AI-generated · cited to primary sources · not investment advice
Shilpa Medicare (530549) Feb 2026 Filing Analysis
Does management do what it says?
The company secured EU approval for the Rotigotine Transdermal Patch ahead of the previously guided Q4 FY26 timeline, receiving it during 3QFY26. (2 exceeded, 3 met across 5 tracked commitments)
“Semaglutide – validation to be completed in 4QFY26, DMF to be readied by 1HFY27”
Management confirmed that the first U.S. NCE program was launched in Q4 FY26 by their big pharma partner. (2 met across 2 tracked commitments)
“GMP facility for ADC is targeted in Q4FY26.”
Management confirmed the successful submission of the Rotigotine Transdermal Patch with the U.S. FDA in Q4 FY26. (1 met across 1 tracked commitment)
“US bioequivalence studies successfully concluded, finalizing our Marketing Application for submission in Q4FY26”
See the full cited Management analysis of Shilpa Medicare
How durable is the business?
The company's technological moat is strengthening as it moves into first-of-its-kind facilities in India, specifically for Antibody Drug Conjugates (ADCs) and recombinant Albumin. They are also entering the high-barrier GLP-1 (peptide) market. (1 expanding)
“GMP facility for our ADC manufacturing, we are planning to commission in Q4 FY '26. It will be first of its kind ADC manufacturing facility in India with integrated payload linker and conjugation facility.”
See the full cited Business Model analysis of Shilpa Medicare
Where does growth come from?
The pipeline is accelerating with concrete regulatory milestones achieved, including EMA authorization for Rotigotine and US FDA suitability petition approval for Tadalafil ODF. (1 accelerating across 1 signal)
“Received final marketing authorization from EMA, gearing up for 1HFY27 launch... The US FDA approved our suitability petition for Tadalafil ODF”
EBITDA margins are accelerating, reaching 28% in 3QFY26 (up 200 bps YoY) and 29% for 9MFY26 (up 300 bps YoY), driven by a shift toward higher-margin complex products. (1 accelerating, 1 steady across 2 signals)
“EBITDA came in at INR 323crs, growing 26% YoY; EBITDA Margins improved by ~300 bps to 29% YoY”
See the full cited Future Growth analysis of Shilpa Medicare
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.